Dem Sorrento seng R&D fokusséiert sech op Innovatioun am COVID-19 ze féieren, Kriibsbehandlung, voll Schmerzkontroll an Autoimmunerkrankungen

Schlëssel Programmer	Indikatioun	Preklinesch	Phase I	Phase II	Phase III / Pivotal	FDA Zertifika
COVID-19 Programmer
COVISTIX™ (Diagnostik) Rapid Antigen Test 0%* Emergency Use Authorization (EUA) a Mexiko (COFEPRIS), Brasilien (ANVISA), an CE Markéiert an Europa COVIMARK™ (Diagnostik) Rapid Antigen Test 0%* Uwendung proposéiert an den USA a Kanada fir Noutverbrauchsautorisatioun (EUA) VIREX (Diagnostik) Doheem Diagnostik 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS wéinst COVID-19 bei ICU Patienten 82%* Pivotal Prozess a Brasilien                           OVYDSO (Olgotrelvir) Anti-viral (Oral Pille) 40%* Omicron mRNA Impfung Impfungen 20%*
Schlëssel Programmer	Indikatioun	Preklinesch	Phase I	Phase II	Phase III / Pivotal	FDA Zertifika
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Zell Lymphom 60.2%* FUJOVEE™ (Abivertinib) Prostata 20%* PD-L1 (Socazolimab)* SCLC 82%* * A Partnerschaft mat Lee's Pharm a China PD-L1 (STI-3031)** Cervical Cancer 82%* ** An den USA an an Zesummenaarbecht mat ImmuneOncia a Korea CD47 Zolitt Tumoren 40%* CD38 DAR-T E puer Myeloma 40%* CD38 ADC Amyloidose, Multiple Myelom, T-ALL, an esophageal 40%* TROP2 ADC* Zolitt Tumoren 40%* Seprehvec™ onkolytesch Virus staark Tumoren; CNS Tumoren 40%* BCMA ADC Flësseg Tumoren 20%* Bevacizumab-ADNAB™ Endometrialkriibs 40%* An Zesummenaarbecht mat Mayo Klinik Bevacizumab-ADNAB™ Ovarial Kriibs 40%* An Zesummenaarbecht mat Mayo Klinik Rituximab-ADNAB™ B-Zell Lymphom 40%* An Zesummenaarbecht mat Mayo Klinik Sofusa® anti-PD-1 Haut T-Zell Lymphom (CTCL), Melanom 40%*
Schlëssel Programmer	Indikatioun	Preklinesch	Phase I	Phase II	Phase III / Pivotal	FDA Zertifika
Pau
ZTlido® 1.8% Postherpetesch Neuralgie - PHN 99.8%* Gloperba® Behandlung vu Gout (mëndlech) 99.8%* SEMDEXA (SP-102) Lendeger Radikulär / Ischias Schmerz 82%* SP-103 (Lidocaine Topical System 5.4%) Akute Réckschmerz 60.2%* SP-104 (Verspéidt Burst Niddereg Dosis Naltrexon) Fibromyalgia 20%* RTX (Resiniferatoxin) Epidural Injektioun Intractable Péng am Fortgeschratt Kriibs 60.3%* Orphan Bezeechnung RTX (Resiniferatoxin) Intraartikuläre Wee Mëttelméisseg bis schwéier Knéi OA Péng 60.2%*
Schlëssel Programmer	Indikatioun	Preklinesch	Phase I	Phase II	Phase III / Pivotal	FDA Zertifika
Lymphatic Drogenofhängeger Liwwerung
Sofusa® Anti-TNF Autoimmun (RA) 40%* Sofusa® anti-PD-1 Haut T-Zell Lymphom (CTCL), Melanom 40%* Sofusa® anti-CTLA-4 Melanoma 40%* An Zesummenaarbecht mat Mayo Klinik

COVID-19 Programmer
Schlëssel Programmer (Indikatioun)	Phase
COVISTIX™ (Diagnostik) FDA EUA COVIMARK™ (Diagnostik) FDA EUA VIREX (Diagnostik) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Impfung Preklinesch

immunotherapy
Schlëssel Programmer (Indikatioun)	Phase
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preklinesch PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Solid Tumoren) Ph I CD38 DAR-T (Multiple Myelom) Ph I CD38 ADC (Amyloidose, Multiple Myelom, T-ALL, an Speiseröh) Ph I TROP2 ADC* (Solid Tumoren) Ph I Seprehvec™ onkolytesch Virus (Solid Tumoren; CNS Tumoren) PH ech BCMA ADC (Flësseg Tumoren) Preklinesch Bevacizumab-ADNAB™ (Endometrium Kriibs) Ph I Bevacizumab-ADNAB™ (Ovarial Cancer) Ph I Rituximab-ADNAB™ (B-Zell Lymphom) Ph I Sofusa® anti-PD-1 (Cutaneous T-Zell Lymphoma (CTCL), Melanom) Ph I

Pau
Schlëssel Programmer (Indikatioun)	Phase
ZTlido® 1.8% (Postherpetesch Neuralgie - PHN) FDA Zertifika Gloperba® 1.8% Behandlung vu Gout (mëndlech) FDA Zertifika SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Verspéidt Burst Niddereg Dosis Naltrexon) Preklinesch RTX (Resiniferatoxin) Epidural Injektioun Ph II RTX (Resiniferatoxin) Intraartikuläre Wee Ph II

Lymphatic Liwwerung
Schlëssel Programmer (Indikatioun)	Phase II
Sofusa® Anti-TNF (Autoimmun RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Zell Lymphoma (CTCL), Melanom) Ph I Sofusa® anti-CTLA-4 (Melanom) Ph I